Decreased COVID-19 Mortality—A Cause for Optimism | Infectious Diseases | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
[Skip to Navigation Landing]
Views 13,050
Citations 0
Invited Commentary
December 22, 2020

Decreased COVID-19 Mortality—A Cause for Optimism

Author Affiliations
  • 1NYC Health + Hospitals, New York
  • 2SUNY Downstate, New York
  • 3New York University School of Medicine, New York
JAMA Intern Med. Published online December 22, 2020. doi:10.1001/jamainternmed.2020.8438

After a hard year, good news related to coronavirus disease 2019 (COVID-19) is welcome. In this issue of JAMA Internal Medicine, Asch and colleagues1 provide a reason for optimism that our health care system has improved in our ability to care for persons with COVID-19. The authors performed a national analysis of COVID-19–associated mortality that spanned 955 US hospitals, representing nearly 40 000 patients. Using administrative claims data from a large national health insurer, they found that a hospital’s risk-standardized event rate (a composite of hospital mortality or referral to hospice) because of COVID-19 had significantly decreased. Specifically, the risk-adjusted mortality decreased from 16.56% to 9.29% in the early period of this study (January through April 2020) compared with the later period (May through June 2020).

Similar improvements in mortality due to COVID-19 have been seen in other studies. A study using national intensive care unit data from the UK2 found a reduction in mortality from 41.4% in March 2020 to 24.8% in June 2020, and a study of patients with COVID-19 in a single hospital system in New York City, New York3 reported that hospital COVID-19–adjusted mortality dropped from 25.6% to 7.6% between March and August 2020. These improvements in mortality likely represent multiple clinical, health care system, and epidemiologic trends.

Clinical Improvements

Since the first wave of serious COVID-19 cases, physicians have learned a great deal about the best ways to treat this serious infection. Steroids may decrease mortality in patients with respiratory failure.4,5 Remdesivir may shorten hospitalizations of patients with serious illness.6 Anticoagulation and prone positioning may help certain patients. Using noninvasive ventilation and high-flow oxygen therapy may spare subsets of patients from the harms of intubation, such as ventilator induced lung injury.

Health Care System

Asch and colleagues1 found that mortality rates were higher when the community prevalence of COVID-19 was higher. One likely reason for this finding is that hospitals do not perform as well when they are overwhelmed. In particular, patients with a precarious respiratory status require expert, meticulous therapy to avoid intubation; those who undergo intubation or have kidney failure require nuanced and timely expert care with ventilatory adjustments and kidney replacement therapy, which are difficult to perform optimally when hospital capacity is strained.

Epidemiologic Factors

Although the care of patients with COVID-19 has undoubtedly improved, it is unlikely that all of the mortality improvement is because of medical care. Patients who were admitted to the hospital during the earlier period likely had greater illness severity in ways that cannot easily be adjusted for. During the spread of cases in the Northeast, patients who did not have acute shortness of breath were told to stay home because the hospitals were overwhelmed. At the time, it was not recognized that a subgroup of patients developed severe hypoxia but were unaware of it. Patients with frailty, especially those in nursing homes, who were disproportionately harmed during the first wave of the epidemic were much better protected from infection in later months, and likely represented a smaller proportion of patients entering the hospital. While COVID-19 cases have also tended to occur among younger persons, the mortality models did adjust for age, so the younger age of more recently infected persons should not affect the adjusted mortality.

A more speculative possibility of why mortality has decreased is the possibility that larger infective doses of COVID-19 may lead to more severe illness than smaller inoculums.7 In the beginning of the first wave, there was very limited use of face masks and social distancing. As 2020 progressed, more people wore masks and distanced themselves, which may have decreased the infecting inoculum. The finding by the authors that the strongest risk factor for a hospital’s standardized event rate was community prevalence of COVID-19 is consistent with this hypothesis, although the connection between inoculum and severity is far from certain.8

Conclusion

COVID-19 has been devastating to health and to society more broadly. Yet there is reason to be proud of how much medical progress, including upcoming vaccines and monoclonal antibodies, as well as increased masking and social distancing, has been made to combat a virus that was unknown until the end of 2019.

Back to top
Article Information

Corresponding Author: Leon Boudourakis, MD, MHS, NYC Health + Hospital/Kings County Hospital, 451 Clarkson Ave, #3211, Brooklyn, NY 11207 (leon.boudourakis@nychhc.org).

Published Online: December 22, 2020. doi:10.1001/jamainternmed.2020.8438

Conflict of Interest Disclosures: None reported.

References
1.
Asch  DA, Sheils  NE, Islam  MN,  et al.  Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic.   JAMA Intern Med. Published online December 22, 2020. doi:10.1001/jamainternmed.2020.8193Google Scholar
2.
Dennis  J, McGovern  A, Vollmer  S, Mateen  BA.  Improving COVID-19 critical care mortality over time in England: a national cohort study, March to June 2020.   medRxiv. Posted online August 3, 2020. doi:10.1101/2020.07.30.20165134Google Scholar
3.
Horwitz,  et al.  Trends in COVID-19 Risk-Adjusted Mortality Rates. Society of Hospital Medicine; 2020.
4.
Horby  P, Lim  WS, Emberson  JR,  et al; RECOVERY Collaborative Group.  Dexamethasone in hospitalized patients with covid-19—preliminary report.   N Engl J Med. 2020.PubMedGoogle Scholar
5.
Sterne  JAC, Murthy  S, Diaz  JV,  et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.  Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis.   JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023PubMedGoogle ScholarCrossref
6.
Beigel  JH, Tomashek  KM, Dodd  LE,  et al; ACTT-1 Study Group Members.  Remdesivir for the treatment of covid-19—final report.   N Engl J Med. 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764PubMedGoogle ScholarCrossref
7.
Gandhi  M, Rutherford  GW.  Facial masking for COVID-19—potential for “variolation” as we await a vaccine.   NEJM. Published online October 29, 2020. doi:10.1056/NEJMp2026913Google Scholar
8.
Rasmussen  AL, Escandron  K, Popescu  SV. Facial masking for Covid (letter). Accessed October 23, 2020. https://www.nejm.org/doi/full/10.1056/NEJMc2030886
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×